DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
14 Oct 2024
Historique:
accepted: 10 10 2024
received: 15 05 2024
revised: 30 05 2024
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: aheadofprint

Résumé

DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the Registry's goals is to continue to refine these guidelines as additional data becomes available. Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the National Cancer Institute Natural History of DICER1 Syndrome study. Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli-Leydig cell tumor (SLCT) at a median age of 14 years (range: 11 months-66 years); 13% were diagnosed under age 8 years, the current age of onset of pelvic surveillance. Additionally, 4% of SLCTs were diagnosed before the age of 4 years. Ongoing data collection highlights the role of lung surveillance in the detection of early PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before age 8 years, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.

Sections du résumé

BACKGROUND BACKGROUND
DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the Registry's goals is to continue to refine these guidelines as additional data becomes available.
EXPERIMENTAL DESIGN METHODS
Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the National Cancer Institute Natural History of DICER1 Syndrome study.
RESULTS RESULTS
Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli-Leydig cell tumor (SLCT) at a median age of 14 years (range: 11 months-66 years); 13% were diagnosed under age 8 years, the current age of onset of pelvic surveillance. Additionally, 4% of SLCTs were diagnosed before the age of 4 years.
CONCLUSION CONCLUSIONS
Ongoing data collection highlights the role of lung surveillance in the detection of early PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before age 8 years, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.

Identifiants

pubmed: 39400264
pii: 749084
doi: 10.1158/1078-0432.CCR-24-1532
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Kris Ann P Schultz (KAP)

Children's Minnesota, Minneapolis, MN, United States.

Alexander T Nelson (AT)

Children's Minnesota, Minneapolis, MN, United States.

Paige H R Mallinger (PHR)

Children's Minnesota, Minneapolis, MN, United States.

Anne K Harris (AK)

International Pleuropulmonary Blastoma Registry and Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, United States.

Junne Kamihara (J)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States.

Kenneth S Chen (KS)

The University of Texas Southwestern Medical Center, Dallas, TX, United States.

Dinel Pond (D)

Children's Minnesota, Minneapolis, MN, United States.

Jessica N Hatton (JN)

National Cancer Institute, Bethesda, MD, United States.

Anna Dybvik (A)

Children's Minnesota, Minneapolis, MN, United States.

Sarah G Mitchell (SG)

Emory University, Atlanta, GA, United States.

Melissa R Perrino (MR)

St. Jude Children's Research Hospital, Memphis, TN, United States.

Tal Ben-Ami (T)

Hebrew University of Jerusalem, Israel.

Denis Kachanov (D)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

Yan Su (Y)

Beijing Children's Hospital, Beijing, China.

Chao Duan (C)

Beijing Children's Hospital, China.

Damon R Olson (DR)

Children's Minnesota, Minneapolis, MN, United States.

Dave Watson (D)

Mayo Clinic, Rochester, MN, United States.

Laura A Harney (LA)

Westat (United States), Rockville, MD, United States.

Ann Garrity Carr (A)

Westat (United States), Olney, MD, United States.

A Lindsay Frazier (AL)

Dana-Farber Cancer Institute, Boston, MA, United States.

Dominik T Schneider (DT)

Klinikum Dortmund, Dortmund, Germany.

David B Wilson (DB)

St. Louis Children's Hospital, United States.

Suzanne P MacFarland (SP)

Children's Hospital of Philadelphia, Philadephia, PA, United States.

Andrew J Bauer (AJ)

Children's Hospital of Philadelphia, Philadelphia, PA, United States.

Louis P Dehner (LP)

Barnes-Jewish and St. Louis Children's Hospitals; Washington University, St. Louis, MO, United States.

D Ashley Hill (DA)

Washington University Medical Center, St. Louis, MO, United States.

Douglas R Stewart (DR)

National Cancer Institute, Bethesda, MD, United States.

Yoav H Messinger (YH)

Children's Minnesota, Minneapolis, MN, United States.

Classifications MeSH